Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Patent number: 8920776Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of variety of leukemias and lymphomas.Type: GrantFiled: January 22, 2003Date of Patent: December 30, 2014Assignee: Corixa CorporationInventors: Alexander Gaiger, Paul A. Algate, Jane Mannion, Jonathan David Clapper, Aijun Wang, Nadia Ordonez, Lauren Carter, Patricia Dianne McNeill
-
Publication number: 20140377173Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.Type: ApplicationFiled: June 24, 2014Publication date: December 25, 2014Inventors: David V. Gold, David M. Goldenberg
-
Publication number: 20140377172Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.Type: ApplicationFiled: March 4, 2010Publication date: December 25, 2014Applicant: Morphogenesis, Inc.Inventors: Michael J.P. Lawman, Patricia Lawman
-
Publication number: 20140377174Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.Type: ApplicationFiled: January 4, 2013Publication date: December 25, 2014Inventors: Hendrik Jan Houthoff, Augustinus A.M.S. Van Dongen, Robbert Jan Kok, Dennis Christian Johannes Waalboer, Sytze Jan Buwalda, Niels Jurriaan Sijbrandi
-
Publication number: 20140369924Abstract: Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.Type: ApplicationFiled: May 12, 2014Publication date: December 18, 2014Inventors: Irving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
-
Publication number: 20140369925Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: May 16, 2014Publication date: December 18, 2014Applicant: AFFITECH RESEARCH ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Publication number: 20140369926Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: J. Andrew BRISTOL, Judith A. KANTOR
-
Patent number: 8911732Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: December 19, 2011Date of Patent: December 16, 2014Assignee: Genentech, Inc.Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
-
Publication number: 20140363372Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.Type: ApplicationFiled: March 24, 2014Publication date: December 11, 2014Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, CHANG GUNG MEMORIAL HOSPITAL, ACADEMIA SINICAInventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok
-
Publication number: 20140363373Abstract: The present invention provides methods and compositions for detecting and treating malignant tissue, organs or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus or by a route providing access to the tissue or organ, with a composition comprising a monoclonal antibody (chimeric, humanized, fully human), partial antibody, Fab Fragment, antibody fragment that is tagged with a fluorophore with or without the addition of a therapeutic chemotherapy molecule, which specifically binds to the targeted organ, tissue or cell. Resection of the primary malignant tissue within the mammalian species (using the fluorescence of the fluorescing targeting construct) provides the advantage of identifying all bulk tumor as fluorescent at the time of the original tumor resection.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Inventor: George A. Luiken
-
Patent number: 8907069Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: July 5, 2010Date of Patent: December 9, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
-
Patent number: 8906342Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: October 14, 2013Date of Patent: December 9, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Debbie Law, Kurt Gish
-
Publication number: 20140348744Abstract: The use of luteinizing hormone receptor (LHR) as a treatment target in cancer is provided. Data demonstrates that LHR plays an important role in androgen synthesis and signaling pathways critical for prostate cancer progression. When LHR is silenced, there is a significant downregulation of androgen receptor (AR) mRNA and protein expression with a subsequent suppression of PSA expression. Data suggesting that the LH-LHR signaling cascade may be an upstream and viable therapeutic target in castration-resistant prostate cancer (CRPC) is presented.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Inventor: Jacek K. Pinski
-
Publication number: 20140348745Abstract: The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.Type: ApplicationFiled: December 12, 2012Publication date: November 27, 2014Inventors: Roy H. Larsen, Jostein Dahle
-
Publication number: 20140348743Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: April 9, 2014Publication date: November 27, 2014Applicants: Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20140341802Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: Woomera TherapeuticsInventors: William G. North, Roy H.L. Pang
-
Publication number: 20140341810Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: WOOMERA THERAPEUTICSInventors: William G. North, Roy H.L. Pang
-
Publication number: 20140335016Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.Type: ApplicationFiled: November 28, 2012Publication date: November 13, 2014Applicant: NEUROPHAGE PHARMACEUTICALS, INC.Inventor: Rajaraman Krishnan
-
Publication number: 20140328751Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 9, 2014Publication date: November 6, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140328752Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: June 3, 2014Publication date: November 6, 2014Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20140328753Abstract: Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.Type: ApplicationFiled: November 15, 2012Publication date: November 6, 2014Applicants: UNIVERSITE BORDEAUX SEGALEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Gisele Clofent-Sanchez, Kamel Deramchia, Marie-Josee Joacobin, Stephane Bonetto, Jeanny Traineau
-
Publication number: 20140322131Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: ApplicationFiled: July 18, 2014Publication date: October 30, 2014Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20140322130Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Publication number: 20140314667Abstract: The present invention relates to methods of treating treating epidermal growth factor deletion mutant vIII (EGFRvIII) related disorders, such as glioblastoma or anaplastic astrocyte tumors, using antigen binding proteins, including antibodies against EGFRvIII conjugated to a drug. Diagnostic and therapeutic formulations of such antibodies and drug conjugates thereof are also provided.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: AMGEN INC.Inventors: John Stephen Hill, Kevin J. Hamblett
-
Publication number: 20140314666Abstract: A system and method for transcellular transport of compositions containing agents (e.g., research, analytical, reporter or molecular probes, diagnostic and therapeutic agents, biologically active agents, research agents, analytical agents, imaging agents, monitoring agents, enzymes, proteins, peptides, nucleic acids, lipids, sugars, hormones, lipoproteins, chemicals, viruses, bacteria, cells, including modified cells, biosensors, markers, antibodies and/or ligands) across the gastrointestinal epithelial layer including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes an anti-ICAM antibody targeting moiety, specific for targeting ICAM-1. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions.Type: ApplicationFiled: June 27, 2014Publication date: October 23, 2014Applicant: UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Silvia Muro Galindo, Rasa Ghaffarian
-
Patent number: 8865122Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.Type: GrantFiled: April 2, 2013Date of Patent: October 21, 2014Assignee: Genentech, Inc.Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
-
Publication number: 20140308204Abstract: The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.Type: ApplicationFiled: October 25, 2012Publication date: October 16, 2014Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Charles Sawyers, David Ulmert, Jason Lewis, Michael Evans, Hans Lija
-
Publication number: 20140308202Abstract: The present invention is drawn to methods of assessing hormonally-regulated cancers such as prostate and breast, by examining the expression of particular genes disregulated in this disease state.Type: ApplicationFiled: April 11, 2014Publication date: October 16, 2014Applicant: VANDERBILT UNIVERSITYInventors: Robert J. Matusik, Renjie Jin, Yajun YI, Fiona E. YULL, Timothy S. Blackwell, Peter E. CLARK, Joseph A. SMITH
-
Publication number: 20140308203Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
-
Publication number: 20140308201Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140301946Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140301945Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 19, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AGInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
-
Patent number: 8852552Abstract: Provided herein are novel compounds based on xanthene, for example biarsenical compounds, which are useful as molecular probes. The compounds contain at least one isotope atom, such as a radioisotope atom. Methods for visualizing tetracysteine-tagged analyte molecules such as proteins using said compounds, methods for synthesizing said compounds, and methods for treating cancer or other hyperproliferative disorders using said compounds are also provided.Type: GrantFiled: November 15, 2011Date of Patent: October 7, 2014Assignee: Biopercept ABInventors: Hans Eric Peter Strom, Samuel Par Simon Svensson
-
Patent number: 8852551Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieties such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: December 11, 2009Date of Patent: October 7, 2014Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Publication number: 20140294722Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang, David V. Gold
-
Publication number: 20140294723Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Applicant: PHILOGEN S.P.A.Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
-
Publication number: 20140294724Abstract: This invention relates to antibody drug conjugates and methods of use thereof. More particularly, antibody drug conjugates comprising a cytoprotective agent are provided, wherein the conjugates are useful for the treatment of proteinopathies such as Alzheimer's disease.Type: ApplicationFiled: October 24, 2012Publication date: October 2, 2014Applicant: INTELLECT NEUROSCIENCES, INC.Inventor: Daniel G. Chain
-
Patent number: 8846005Abstract: The invention provides, inter alia, methods for methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with APCDD1 overexpression.Type: GrantFiled: March 14, 2008Date of Patent: September 30, 2014Assignee: Novartis AGInventors: Mary J. Janatpour, Abdallah Fanidi, Shanling Shen, Karen Yu
-
Publication number: 20140286859Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: ApplicationFiled: September 10, 2012Publication date: September 25, 2014Applicants: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20140286862Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: October 26, 2012Publication date: September 25, 2014Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20140286861Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: April 23, 2014Publication date: September 25, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140286860Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.Type: ApplicationFiled: April 22, 2014Publication date: September 25, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
-
Publication number: 20140271462Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Applicant: IMAGINAB, INC.Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
-
Publication number: 20140271463Abstract: The disclosure relates to the use of altered BRI2 levels as a biomarker for the risk of developing Alzheimer's disease. Novel treatments based on altered BRI2 levels and anti-BRI2 antibodies are also provided.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Stichting VU-VUmcInventors: Marta DEL CAMPO MILAN, Cornelia Ramona Jimenez, Chrlott Elisabeth Teunissen
-
Publication number: 20140271464Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Alderbio Holdings LLCInventors: Leon F. GARCIA-MARTINEZ, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
-
Publication number: 20140255304Abstract: Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicants: BIOGEN IDEC INTERNALTIONAL NEUROSCIENCE GMBH, UNIVERSITY OF ZURICHInventors: Nitsch Roger, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140255303Abstract: The present invention relates to nanobodies specifically directed against VCAM-1 and to their use in medical imaging and in diagnostic, prognostic and treatment methods.Type: ApplicationFiled: August 22, 2012Publication date: September 11, 2014Applicant: UNIVERSITE JOSEPH FOURIER- GRENOBLE 1Inventors: Catherine Ghezzi, Daniel Fagret, Alexis Broisat, Nick Devoogdt, Tony Lahoutte, Serge Muydermans
-
Publication number: 20140255301Abstract: Methods of identifying, diagnosing, and prognosing a neurodegenerative disease, or disorder, are provided. Also provided are methods for determining whether a neuron is at risk or is undergoing neurodegeneration. The methods comprise determining whether at least one of the genes tbx6 and dleu2 is overexpressed.Type: ApplicationFiled: November 28, 2011Publication date: September 11, 2014Inventors: Mark Chen, Ryan J. Watts